Spina bifida
diseaseOn this page
Also known as neural tube defects, susceptibility toNTDrachischisisspina bifida (disease)spinal meningocelespinal myelocelespinal myelomeningocele
Summary
Spina bifida (MONDO:0008449) is a disease with 1 cohort gene (3 GWAS associations across 3 studies) and 102 clinical trials. Top therapeutic interventions include oxybutynin chloride and pamidronic acid.
At a glance
- Cohort genes: 1
- GWAS associations: 3
- Clinical trials: 102
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | spina bifida |
| Mondo ID | MONDO:0008449 |
| EFO | EFO:0003105 |
| MeSH | D016135 |
| DOID | DOID:0080016 |
| ICD-10-CM | Q05 |
| ICD-11 | 2036217905 |
| NCIT | C101214 |
| SNOMED CT | 67531005 |
| UMLS | C0080178 |
| MedGen | 38283 |
| Is cancer (heuristic) | no |
Also known as: neural tube defects, susceptibility to · NTD · rachischisis · spina bifida · spina bifida (disease) · spinal meningocele · spinal myelocele · spinal myelomeningocele
Data availability: 3 GWAS associations (3 studies) · 1 GenCC gene-disease record · 1 HPO phenotype · 6 cell lines.
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › congenital nervous system disorder › spina bifida
Related subtypes (216): polymicrogyria, congenital myasthenic syndrome with tubular aggregates, prenatal-onset spinal muscular atrophy with congenital bone fractures, anencephaly, cerebral cavernous malformation, meningocele, progressive external ophthalmoplegia, congenital nystagmus, congenital toxoplasmosis, congenital contractural arachnodactyly, congenital trigeminal anesthesia, familial congenital palsy of trochlear nerve, Myhre syndrome, Aase-Smith syndrome, KBG syndrome, autosomal dominant primary microcephaly, Mobius syndrome, MYH7-related skeletal myopathy, congenital stationary night blindness autosomal dominant 2, Prader-Willi syndrome, congenital myopathy 7A, myosin storage, autosomal dominant, Smith-Magenis syndrome, Freeman-Sheldon syndrome, isolated cerebellar hypoplasia/agenesis, Chediak-Higashi syndrome, Cohen syndrome, multiple pterygium-malignant hyperthermia syndrome, corpus callosum, agenesis of, congenital lactic acidosis, Saguenay-Lac-Saint-Jean type, facial dysmorphism-macrocephaly-myopia-Dandy-Walker malformation syndrome, diastematomyelia, EEM syndrome, Mowat-Wilson syndrome, Johanson-Blizzard syndrome, intellectual disability, Buenos-Aires type, myasthenia, congenital, refractory to acetylcholinesterase inhibitors, congenital myasthenic syndrome 6, Bailey-Bloch congenital myopathy, congenital stationary night blindness 1B, radioulnar synostosis-developmental delay-hypotonia syndrome, Schinzel-Giedion syndrome, schizencephaly, intellectual disability, Wolff type, X-linked intellectual disability-plagiocephaly syndrome, X-linked adrenal hypoplasia congenita, syndromic X-linked intellectual disability 7, syndromic X-linked intellectual disability Shashi type, syndromic X-linked intellectual disability Lubs type, syndromic X-linked intellectual disability Abidi type, syndromic X-linked intellectual disability Siderius type, X-linked intellectual disability, Cabezas type, X-linked intellectual disability-cubitus valgus-dysmorphism syndrome, syndromic X-linked intellectual disability Claes-Jensen type, moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome, multiple congenital anomalies-hypotonia-seizures syndrome 2, developmental and epileptic encephalopathy, 36, blepharophimosis - intellectual disability syndrome, MKB type, X-linked intellectual disability-short stature-overweight syndrome, intellectual disability, X-linked, syndromic 33, syndromic X-linked intellectual disability 34, infantile-onset X-linked spinal muscular atrophy, syndromic X-linked intellectual disability 5, holoprosencephaly-hypokinesia-congenital contractures syndrome, X-linked intellectual disability with marfanoid habitus, Wieacker-Wolff syndrome, MERRF syndrome, macrocephaly-spastic paraplegia-dysmorphism syndrome, intellectual disability-sparse hair-brachydactyly syndrome, myofibrillar myopathy 1, isolated hereditary congenital facial paralysis, fibrosis of extraocular muscles, congenital, 2, Pierpont syndrome, congenital cataracts-facial dysmorphism-neuropathy syndrome, Bohring-Opitz syndrome, PHACE syndrome, B4GALT1-congenital disorder of glycosylation, developmental malformations-deafness-dystonia syndrome, sensory ataxic neuropathy, dysarthria, and ophthalmoparesis, AICA-ribosiduria, myofibrillar myopathy 3, fibrosis of extraocular muscles, congenital, 3c, myofibrillar myopathy 4, myofibrillar myopathy 5, cone-rod synaptic disorder, congenital nonprogressive, congenital stationary night blindness autosomal dominant 3, congenital stationary night blindness autosomal dominant 1, intellectual disability, autosomal recessive 12, progressive myoclonic epilepsy type 3, chromosome 15q13.3 microdeletion syndrome, combined pituitary hormone deficiencies, genetic form, congenital stationary night blindness 1D, DYRK1A-related intellectual disability syndrome, Pitt-Hopkins-like syndrome 2, developmental and epileptic encephalopathy, 15, Schuurs-Hoeijmakers syndrome, severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome, severe intellectual disability-progressive spastic diplegia syndrome, hypotonia, infantile, with psychomotor retardation and characteristic facies, developmental and epileptic encephalopathy, 18, CTCF-related neurodevelopmental disorder, autism spectrum disorder due to AUTS2 deficiency, developmental and epileptic encephalopathy, 23, ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder, Bardet-Biedl syndrome 11, cerebellar-facial-dental syndrome, fibrosis of extraocular muscles, congenital, 5, congenital myasthenic syndrome 15, lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome, autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome, congenital myasthenic syndrome 18, autosomal recessive spinocerebellar ataxia 20, Houge-Janssens syndrome 1, intellectual disability-microcephaly-strabismus-behavioral abnormalities syndrome, congenital stationary night blindness 1G, hypomyelinating leukodystrophy 10, developmental and epileptic encephalopathy, 50, congenital insensitivity to pain-hypohidrosis syndrome, macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome, SLC39A8-CDG, spastic paraplegia-severe developmental delay-epilepsy syndrome, cardiac anomalies - developmental delay - facial dysmorphism syndrome, severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome, intellectual disability, autosomal recessive 53, TELO2-related intellectual disability-neurodevelopmental disorder, micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome, autosomal recessive limb-girdle muscular dystrophy type 2Y, myofibrillar myopathy 7, short stature-brachydactyly-obesity-global developmental delay syndrome, autosomal recessive limb-girdle muscular dystrophy type 2R1, severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome, congenital laryngeal palsy, congenital or early infantile CACH syndrome, congenital epulis, severe congenital nemaline myopathy, intermediate nemaline myopathy, typical nemaline myopathy, childhood-onset nemaline myopathy, adult-onset nemaline myopathy, qualitative or quantitative defects of protein involved in O-glycosylation of alpha-dystroglycan, holoprosencephaly, congenital insensitivity to pain with hyperhidrosis, congenital hydrocephalus, familial congenital mirror movements, macrocephaly-short stature-paraplegia syndrome, cephalocele, mitochondrial neurogastrointestinal encephalomyopathy, X-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome, 7p22.1 microduplication syndrome, congenital achiasma, congenital retinal arteriovenous communication, 3q27.3 microdeletion syndrome, Prader-Willi-like syndrome, 9q31.1q31.3 microdeletion syndrome, congenital oculomotor nerve palsy, congenital abducens nerve palsy, neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-hip dysplasia syndrome, congenital insensitivity to pain with severe intellectual disability, X-linked intellectual disability-cerebellar hypoplasia-spondylo-epiphyseal dysplasia syndrome, global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome, lissencephaly spectrum disorders, hyaline body myopathy, 22q11.2 deletion syndrome, craniorachischisis, Leber congenital amaurosis, Ritscher-Schinzel syndrome, Rubinstein-Taybi syndrome, X-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome, X-linked intellectual disability-epilepsy-progressive joint contractures-dysmorphism syndrome, X-linked intellectual disability, Pai type, X-linked intellectual disability, Stevenson type, X-linked intellectual disability, Stoll type, congenital muscular dystrophy, congenital vitreoretinal dysplasia, periventricular nodular heterotopia, postsynaptic congenital myasthenic syndrome, subcortical band heterotopia, congenital fibrosis of extraocular muscles type 1, Al Gazali Khidr Prem Chandran syndrome, distal arthrogryposis Moore weaver type, congenital myotonic dystrophy, myasthenic syndrome, congenital, 7B, presynaptic, autosomal recessive, intellectual disability, autosomal dominant 47, intellectual disability, autosomal dominant 48, spondyloepiphyseal dysplasia, sensorineural hearing loss, impaired intellectual development, and leber congenital amaurosis, myasthenic syndrome, congenital, 23, presynaptic, myasthenic syndrome, congenital, 24, presynaptic, myasthenic syndrome, congenital, 25, presynaptic, developmental and epileptic encephalopathy, 77, night blindness, congenital stationary, type1i, neuropathy, congenital hypomelinating, congenital axonal neuropathy with encephalopathy, developmental and epileptic encephalopathy, 73, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, isolated exencephaly, myasthenic syndrome, congenital, 22, intellectual developmental disorder with gastrointestinal difficulties and high pain threshold, intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, 9q33.3q34.11 microdeletion syndrome, congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome, early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome, SIN3A-related intellectual disability syndrome, childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder, X-linked congenital stationary night blindness, neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, FOXG1 disorder, alpha-actinopathy, TPM3-related myopathy, X-linked recessive mitochondrial myopathy, RYR1-related myopathy, TTN-related myopathy, TPM2-related myopathy, myopathy caused by variation in POMGNT1, central hypoventilation syndrome, congenital, 1, with or without Hirschsprung disease, segmental spinal dysgenesis, myopathy, myofibrillar, 13, with rimmed vacuoles, congenital neuronal ceroid lipofuscinosis 10
Subtypes (2): spina bifida occulta, isolated spina bifida
Genetics & variants
GWAS landscape
3 GWAS associations across 3 studies. Top hits map to 3 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs75426652 | 7e-14 | LHPP | A | |
| rs45580033 | 4e-10 | ASB2 | A | |
| rs140199800 | 2e-07 | SULT1C2 | A |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90474255 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 387 | 458,053 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90436766 | Zhou W | 2018 | 210 | 408,394 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90566547 | Tindula G | 2024 | 65 | 0 | Genome-wide analysis of spina bifida risk variants in a case-control study from Bangladesh. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 3 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 0 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 2 |
Functional consequences
| Consequence | Count |
|---|---|
| missense_variant | 2 |
| stop_gained | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs75426652 | 10 | 124461954 | C>A,G,T | 0.05 | missense_variant | LHPP | 7e-14 | Tier 1: coding |
| rs45580033 | 14 | 93964365 | G>A,C,T | missense_variant | ASB2 | 4e-10 | Tier 1: coding | |
| rs140199800 | 2 | 108293753 | G>A | stop_gained | SULT1C2 | 2e-07 | Tier 1: coding |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 1 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| FKBP8 | Moderate | Autosomal dominant | spina bifida |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| FKBP8 | HGNC:3724 | ENSG00000105701 | Q14318 | Peptidyl-prolyl cis-trans isomerase FKBP8 | gencc |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| FKBP8 | Peptidyl-prolyl cis-trans isomerase FKBP8 | Constitutively inactive PPiase, which becomes active when bound to calmodulin and calcium. |
Protein-family classification
Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Enzyme (other) | 1 | 12.0× | 0.083 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| FKBP8 | Enzyme (other) | yes | 5.2.1.8 | PPIase_FKBP_dom, TPR-like_helical_dom_sf, TPR_rpt |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| left testis | 1 |
| right frontal lobe | 1 |
| right testis | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| FKBP8 | 253 | ubiquitous | marker | right frontal lobe, right testis, left testis |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| FKBP8 | 4,491 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| FKBP8 | Q14318 | 6 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Ub-specific processing proteases | 1 | 53.1× | 0.019 | FKBP8 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| protein localization to mitochondrion | 1 | 1296.3× | 0.005 | FKBP8 |
| regulation of mitophagy | 1 | 1203.7× | 0.005 | FKBP8 |
| dorsal/ventral neural tube patterning | 1 | 802.5× | 0.005 | FKBP8 |
| neuron fate specification | 1 | 702.2× | 0.005 | FKBP8 |
| negative regulation of protein phosphorylation | 1 | 581.1× | 0.005 | FKBP8 |
| positive regulation of BMP signaling pathway | 1 | 455.5× | 0.005 | FKBP8 |
| camera-type eye development | 1 | 358.6× | 0.006 | FKBP8 |
| BMP signaling pathway | 1 | 200.6× | 0.009 | FKBP8 |
| smoothened signaling pathway | 1 | 181.2× | 0.009 | FKBP8 |
| multicellular organism growth | 1 | 137.0× | 0.011 | FKBP8 |
| protein folding | 1 | 103.4× | 0.013 | FKBP8 |
| regulation of gene expression | 1 | 83.4× | 0.015 | FKBP8 |
| intracellular signal transduction | 1 | 38.1× | 0.030 | FKBP8 |
| negative regulation of apoptotic process | 1 | 34.8× | 0.031 | FKBP8 |
| apoptotic process | 1 | 28.7× | 0.035 | FKBP8 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| FKBP8 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| FKBP8 | 2 | Binding:2 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| FKBP8 | 5.2.1.8 | peptidylprolyl isomerase |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 1 | FKBP8 |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| FKBP8 | 2 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 102.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 99 |
| PHASE2 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07027020 | PHASE3 | RECRUITING | Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction |
| NCT00359775 | PHASE2 | COMPLETED | Coping Skills Training (CST) for Children With Chronic Health Conditions |
| NCT00378664 | PHASE2 | COMPLETED | Lumbar to Sacral Ventral Nerve Re-Routing |
| NCT00891891 | Not specified | ACTIVE_NOT_RECRUITING | Psychosocial Adjustment of Adolescents With Spina Bifida |
| NCT02592291 | Not specified | RECRUITING | Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions |
| NCT03090633 | Not specified | ACTIVE_NOT_RECRUITING | Fetoscopic Repair of Isolated Fetal Spina Bifida |
| NCT03410667 | Not specified | ACTIVE_NOT_RECRUITING | Incontinence and Quality of Life in Children With Spina Bifida |
| NCT03698721 | Not specified | NOT_YET_RECRUITING | Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate |
| NCT03856034 | Not specified | RECRUITING | Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele |
| NCT04243889 | Not specified | ACTIVE_NOT_RECRUITING | Fetoscopic NEOX Cord 1K® Spina Bifida Repair |
| NCT04362592 | Not specified | ACTIVE_NOT_RECRUITING | In-Utero Endoscopic Correction of Spina Bifida |
| NCT04770805 | Not specified | ACTIVE_NOT_RECRUITING | In Utero Fetoscopic Repair Program for Sacral Myelomeningoceles and Mye-LDM |
| NCT05117827 | Not specified | ACTIVE_NOT_RECRUITING | Pediatric Powered Wheelchair Standing Devices: An Exploratory Study |
| NCT05253196 | Not specified | NOT_YET_RECRUITING | Enema Device for Children With Spina Bifida |
| NCT05339932 | Not specified | ACTIVE_NOT_RECRUITING | Grand Valley State University (GVSU) Skills on Wheels |
| NCT05726591 | Not specified | RECRUITING | Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders |
| NCT05784285 | Not specified | NOT_YET_RECRUITING | Downstream Effects of Personalized ‘Top-down’ Participation-based Interventions Among Youth With Physical Disabilities |
| NCT05849285 | Not specified | RECRUITING | Evaluation of the Transitional and Lifelong Care Program |
| NCT06025734 | Not specified | RECRUITING | Transcutaneous Tibial Nerve Stimulation (TTNS) Treatment in Spina Bifida Pediatric Patients With Neurogenic Bladder |
| NCT06041334 | Not specified | RECRUITING | Evaluation of muLtimodal and Non-invasive SPINa Bifida Neurovessels During Prospective Follow-up |
| NCT06419049 | Not specified | RECRUITING | Impact of Standing Programs in Children With Spina Bifida: A Single Subject Design |
| NCT06618378 | Not specified | NOT_YET_RECRUITING | Effectiveness of Biofeedback Training in Children with Neurogenic Bladder and Bowel Disorder Wıth Spina Bifida |
| NCT06723951 | Not specified | RECRUITING | QUALAS Validation in Dutch |
| NCT06802770 | Not specified | ACTIVE_NOT_RECRUITING | Evaluation of Depression and Anxiety Levels of Parents of Children with Spina Bifida |
| NCT06828653 | Not specified | RECRUITING | Comparing Digitally and Traditionally Made Ankle Foot Orthoses |
| NCT06918119 | Not specified | RECRUITING | Transcutaneous Spinal Stimulation for Children and Youth With Spina Bifida |
| NCT06929572 | Not specified | RECRUITING | Autologous Human Umbilical Cord Tissue Patch for Postnatal Closure of Open Neural Tube Defects |
| NCT06946563 | Not specified | RECRUITING | Fetoscopic Neural Tube Defect Repair |
| NCT07178873 | Not specified | RECRUITING | Psychosocial Teleassistance Programme for Adults With Spina Bifida |
| NCT07290556 | Not specified | NOT_YET_RECRUITING | Establishing the Preliminary Utility of a Novel Pediatric Manual Mobile Standing Wheelchair |
| NCT07390318 | Not specified | RECRUITING | Bowel Continence Across the Lifespan in People With Spina Bifida |
| NCT07531862 | Not specified | NOT_YET_RECRUITING | Spina Bifida Healthcare Navigator Program |
| NCT07615686 | Not specified | RECRUITING | tSCS in Children With Spina Bifida |
| NCT00031122 | Not specified | UNKNOWN | Study of Genetic Risk Factors for Spina Bifida and Anencephaly |
| NCT00655681 | Not specified | COMPLETED | Prevention of Post Operative Bone Loss in Children |
| NCT00720161 | Not specified | COMPLETED | Metformin in Children With Motor Deficit |
| NCT00866112 | Not specified | COMPLETED | A Randomized Exercise Trial for Wheelchair Users |
| NCT00951509 | Not specified | COMPLETED | Virtual Reality Based Testing of Power Wheelchair Driving Skills |
| NCT01096459 | Not specified | WITHDRAWN | Nerve Rerouting Treatment for Neurogenic Bladder in Spina Bifida |
| NCT01133288 | Not specified | TERMINATED | Yulex Glove Prospective Study in Spina Bifida |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| OXYBUTYNIN CHLORIDE | 4 | 1 |
| PAMIDRONIC ACID | 4 | 1 |
Related Atlas pages
- Cohort genes: FKBP8
- Drugs: Oxybutynin Chloride, Pamidronic Acid
- Associated genes: AMBRA1, CCL2, CELSR1, FUZ, VANGL1, VANGL2